1-866-390-4411 info@x-gen.us

Big Flats, NY., August 1st, 2019 –

X-GEN Pharmaceuticals announced today the immediate availability in the United States of Dactinomycin for Injection, USP. Dactinomycin is an actinomycin indicated for the treatment of:
• adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen.
• adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen.
• adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen.
• adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen.
• post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen.
• adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion.